SOLS Stock Analysis: Solstice Advanced Materials | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 9.616m USD | 12M Return: 25.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 255M
Rev. Trend: 100.0%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solstice Advanced Materials, Inc. (NASDAQ: SOLS) is a U.S.-headquartered specialty chemicals and advanced materials company that operates through two segments: Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM). The RAS segment produces low global-warming-potential (LGWP) refrigerants, blowing agents, solvents, and aerosol materials marketed under the Solstice, Genetron, and Aclar brands, while the ESM segment supplies electronic materials, high-strength fibers, and life-science chemicals for semiconductor, defense, pharmaceutical, and construction end-markets under the Spectra, Fluka, and Hydranal brands. The company recently completed its IPO on October 29, 2025, and is incorporated and headquartered in Morris Plains, New Jersey.
As a specialty chemicals producer, Solstice focuses on differentiated, formulation-intensive products rather than high-volume commodity chemicals, which generally supports higher margins but exposes results to feedstock volatility. Its LGWP refrigerant portfolio is positioned to benefit from regulatory phase-downs of high-GWP HFCs under frameworks such as the U.S. AIM Act and the Kigali Amendment, while its semiconductor and life-science materials businesses target end-markets with structural demand growth tied to electronics manufacturing and pharmaceutical research.
- AIM Act mandates accelerate low-GWP refrigerant adoption
- Semiconductor sputtering target demand tracks AI chip capex
- Pharma packaging Aclar sales grow with biologics expansion
| Net Income: 107.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -7.20 > 1.0 |
| NWC/Revenue: 18.37% < 20% (prev 27.49%; Δ -9.13% < -1%) |
| CFO/TA 0.09 > 3% & CFO 494.0m > Net Income 107.0m |
| Net Debt (1.89b) to EBITDA (856.0m): 2.21 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.3m) vs 12m ago 0.37% < -2% |
| Gross Margin: 31.18% > 18% (prev 34.79%; Δ -3.61% > 0.5%) |
| Asset Turnover: 71.04% > 50% (prev 67.66%; Δ 3.38% > 0%) |
| Interest Coverage Ratio: 5.07 > 6 (EBIT TTM 634.0m / Interest Expense TTM 125.0m) |
| A: 0.13 (Total Current Assets 2.44b - Total Current Liabilities 1.71b) / Total Assets 5.75b |
| B: 0.02 (Retained Earnings 113.0m / Total Assets 5.75b) |
| C: 0.11 (EBIT TTM 634.0m / Avg Total Assets 5.60b) |
| D: 0.35 (Book Value of Equity 1.49b / Total Liabilities 4.28b) |
| Altman-Z'' = 2.02 = BBB |
| DSRI: 1.33 (Receivables 943.0m/659.0m, Revenue 3.98b/3.69b) |
| GMI: 1.12 (GM 34.79% / 31.18%) |
| AQI: 0.83 (AQ_t 0.21 / AQ_t-1 0.26) |
| SGI: 1.08 (Revenue 3.98b / 3.69b) |
| TATA: -0.07 (NI 107.0m - CFO 494.0m) / TA 5.75b) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of July 29, 2026, the stock is trading at USD 60.59 with a total of 3,918,427 shares traded. Over the past week, the price has changed by +7.30%, over one month by -26.59%, over three months by -25.47% and over the past year by +25.42%.
Current recommended Stop Loss: 55.60 (which is 8.2% or 1.3 ATR below the current price).
Solstice Advanced Materials has no consensus analysts rating.
P/E Trailing = 51.7436
P/E Forward = 22.6757
P/S = 2.4156
P/B = 6.4713
P/EG = 0.7846
Revenue TTM = 3.98b USD
EBIT TTM = 634.0m USD
EBITDA TTM = 856.0m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 351.0m USD (from shortTermDebt, last quarter)
Debt = 2.53b USD (from shortLongTermDebtTotal, last quarter) + Leases 114.0m
Net Debt = 1.89b USD (calculated: Debt 2.53b - CCE 642.0m)
Enterprise Value = 11.5b USD (9.62b + Debt 2.53b - CCE 642.0m)
Interest Coverage Ratio = 5.07 (Ebit TTM 634.0m / Interest Expense TTM 125.0m)
EV/FCF = 89.18x (Enterprise Value 11.5b / FCF TTM 129.0m)
FCF Yield = 1.12% (FCF TTM 129.0m / Enterprise Value 11.5b)
FCF Margin = 3.24% (FCF TTM 129.0m / Revenue TTM 3.98b)
Net Margin = 2.69% (Net Income TTM 107.0m / Revenue TTM 3.98b)
Gross Margin = 31.18% ((Revenue TTM 3.98b - Cost of Revenue TTM 2.74b) / Revenue TTM)
Gross Margin QoQ = 31.89% (prev 26.14%)
Tobins Q-Ratio = 2.00 (Enterprise Value 11.5b / Total Assets 5.75b)
Interest Expense / Debt = 4.94% (Interest Expense 125.0m / Debt 2.53b)
Taxrate = 22.79% (31.0m / 136.0m)
NOPAT = 489.5m (EBIT 634.0m * (1 - 22.79%))
Current Ratio = 1.43 (Total Current Assets 2.44b / Total Current Liabilities 1.71b)
Debt / Equity = 1.70 (Debt 2.53b / totalStockholderEquity, last quarter 1.49b)
Debt / EBITDA = 2.21 (Net Debt 1.89b / EBITDA 856.0m)
Debt / FCF = 14.64 (Net Debt 1.89b / FCF TTM 129.0m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.91% (Net Income 107.0m / Total Assets 5.75b)
RoE = 5.82% (Net Income TTM 107.0m / Total Stockholder Equity 1.84b)
RoCE = 16.60% (EBIT 634.0m / Capital Employed (Equity 1.84b + L.T.Debt 1.98b))
RoIC = 11.67% (NOPAT 489.5m / Invested Capital 4.20b)
WACC = 6.67% (E(9.62b)/V(12.1b) * Re(7.42%) + D(2.53b)/V(12.1b) * Rd(4.94%) * (1-Tc(0.23)))
Discount Rate = 7.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.57 | Cagr: 0.21%
[DCF] Terminal Value 73.10% ; FCFF base≈283.6m ; Y1≈248.7m ; Y5≈200.9m
[DCF] Fair Price = 8.42 (EV 3.23b - Net Debt 1.89b = Equity 1.34b / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.98 | Revenue CAGR: 3.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.77 | Chg30d=+0.91% | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.66 | Chg30d=-1.05% | Revisions=-40% | Analysts=6
EPS current Year (2026-12-31): EPS=2.65 | Chg30d=+0.51% | Revisions=+0% | GrowthEPS=+78.0% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=3.21 | Chg30d=+1.21% | Revisions=+40% | GrowthEPS=+21.0% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: +0% (up=4, down=4)